Anti-inflammatory effects of oxymatrine through inhibition of nuclear factor-kappa B and mitogen-activated protein kinase activation in lipopolysaccharide-induced BV2 microglia cells

Iranian Journal of Pharmaceutical Research

Volumn 12, Issue 1, 2013, Pages 165-174

  Dong, Xiao Qiao ^a   Du, Quan ^a   Yu, Wen Hua ^a   Zhang, Zu Yong ^a   Zhu, Qiang ^a   Che, Zhi Hao ^a   Chen, Feng ^a   Wang, Hao ^a   Chen, Jun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Inflammation; Microglia; Mitogen activated protein kinase; Nuclear factor kappa B; Oxymatrine

Indexed keywords

CYCLOOXYGENASE 2; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; OXYMATRINE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; MICROGLIA; NONHUMAN; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84874671239     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Zeng Z, Wang GJ and Si CW. Basic and clinical study of oxymatrine on HBV infection. J. Gastroenterol. Hepatol. (1999) 14: 295-297.
2. Chen XS, Wang GJ, Cai X, Yu HY and Hu YP. Inhibition of hepatitis B virus by oxymatrine in-vivo. World J. Gastroenterol. (2001) 7:49-52.
3. Dong Y, Xi H, Yu Y, Wang Q, Jiang K and Li L. Effects of oxymatrine on the serum levels of T helper cell 1 and 2 cytokines and the expression of the S gene in hepatitis B virus S gene transgenic mice: a study on the anti-hepatitis B virus mechanism of oxymatrine. J. Gastroenterol. Hepatol. (2002) 17:1299-1306.
4. Xiang X, Wang G, Cai X and Li Y. Effect of oxymatrine on murine fulminant hepatitis and hepatocyte apoptosis. Chin. Med. J. (2002) 115: 593-596.
5. Lu LG, Zeng MD, Mao YM, Li JQ, Wan MB, Li CZ, Chen CW, Fu QC, Wang JY, She WM, Cai X, Ye J, Zhou XQ, Wang H, Wu SM, Tang MF, Zhu JS, Chen WX and Zhang HQ. Oxymatrine therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multi-center trial. World J. Gastroenterol. (2003) 9: 2480-2483.
6. Lu LG, Zeng MD, Mao YM, Fang JY, Song YL, Shen ZH and Cao AP. Inhibitory effect of oxymatrine on serum hepatitis B virus DNA in HBV transgenic mice. World J. Gastroenterol. (2004) 10: 1176-1179.
7. Mao YM, Zeng MD, Lu LG, Wan MB, Li CZ, Chen CW, Fu QC, Wang JY, She WM, Cai X, Ye J, Zhou XQ, Wang H, Wu SM, Tang MF, Zhu JS, Chen WX and Zhang HQ. Capsule oxymatrine in treatment of hepatic fbrosis due to chronic viral hepatitis: a randomized, double blind, placebo-controlled, multicenter clinical study. World J. Gastroenterol. (2004) 10: 3269-3273.
8. Hong-Li S, Lei L, Lei S, Dan Z, De-Li D, Guo-Fen Q, Yan L, Wen-Feng C and Bao-Feng Y. Cardioprotective effects and underlying mechanisms of oxymatrine against ischemic myocardial injuries of rats. Phytother. Res. (2008) 22: 985-989.
9. Zhao J, Yu S, Tong L, Zhang F, Jiang X, Pan S, Jiang H and Sun X. Oxymatrine attenuates intestinal ischemia/ reperfusion injury in rats. Surg. Today. (2008) 38: 931-937.
10. Xu GL, Yao L, Rao SY, Gong ZN, Zhang SQ and Yu SQ. Attenuation of acute lung injury in mice by oxymatrine is associated with inhibition of phosphorylated p38 mitogen-activated protein kinase. J. Ethnopharmacol. (2005) 98: 177-183.
11. Zheng P, Niu FL, Liu WZ, Shi Y and Lu LG. Anti-infammatory mechanism of oxymatrine in dextran sulfate sodium-induced colitis of rats. World J. Gastroenterol. (2005) 11: 4912-4915.
12. Yuan X, Sun Y, Miao N, Sun S, Wang Y, Hu Z, Yuan J, Xu M and Liu Z. The synergistic anti-infammatory effect of the combination of sodium ferulate and oxymatrine and its modulation on infammation-associated mediators in RAW 264.7 cells. J. Ethnopharmacol. (2011) 137: 1477-1485.
13. Liu Y, Zhang XJ, Yang CH and Fan HG. Oxymatrine protects rat brains against permanent focal ischemia and downregulates NF-kappaB expression. Brain Res. (2009) 1268: 174-180.
14. Fan H, Li L, Zhang X, Liu Y, Yang G, Yang Y and Yin J. Oxymatrine downregulates TLR4, TLR2, MyD88, and NF-kappaB and protects rat brains against focal ischemia. Mediators Infamm. (2009) doi:10.1155/2009/704706.
15. Cui L, Zhang X, Yang R, Wang L, Liu L, Li M and Du W. Neuroprotection and underlying mechanisms of oxymatrine in cerebral ischemia of rats. Neurol. Res. (2011) 33: 319-324.
16. Dong, XQ, Yu WH, Hu YY, Zhang ZY and Huang M. Oxymatrine reduces neuronal cell apoptosis by inhibiting Toll-like receptor 4/nuclear factor kappa-B-dependent infammatory responses in traumatic rat brain injury. Infamm. Res. (2011) 60: 533-539.
17. Stoll G and Jander S. The role of microglia and macrophages in the pathophysiology of the CNS. Prog. Neurobiol. (1999) 58: 233-247.
18. Perry VH and Gordon S. Macrophages and microglia in the nervous system. Trends Neurosci. (1988) 92: 273-274.
19. Lee Y, Nagai A and Kim SU. Cytoines, chemokines and cytokine receptors in human microglia. J. Neurosci. Res. (2002) 69: 94-103.
20. Banati RB, Gehrmann J, Schubert P and Kreutzberg GW. Cytotoxicity of microglia. Glia. (1993) 7: 111-118.
21. Giulian D and Corpuz M. Microglial secretion products and their impact on the nervous system. Adv. Neurol. (1993) 59: 315-320.
22. Giulian D, Li J, Li X, George J and Rutecki PA. The impact of microglia-derived cytokines upon gliosis in the CNS. Dev. Neurosci. (1994) 16: 128-136.
23. Zielasek J and Hartung HP. Molecular mechanisms of microglial activation. Adv. Neuroimmunol. (1996) 6: 191-202.
24. McGeer PL and McGeer EG. The infammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev. (1995) 21: 195-218.
25. McGeer PL, Kawamata T, Walker DG, Akiyama H, Tooyama I and McGeer EG. Microglia in degenerative neurological disease. Glia. (1993) 7: 84-92.
26. Rock RB and Peterson PK. Microglia as a pharmacological target in infectious and infammatory diseases of the brain. J. Neuroimmune Pharmacol. (2006) 1: 117-126.
27. Kim HS, Whang SY, Woo MS, Park JS, Kim WK and Han IO. Sodium butyrate suppresses interferon-gamma-, but not lipopolysaccharide-mediated induction of nitric oxide and tumor necrosis factor-alpha in microglia. J. Neuroimmunol. (2004) 151: 85-93.
28. Kim WK, Jang PG, Woo MS, Han IO, Piao HZ, Lee K, Lee H, Joh TH and Kim HS. A new anti-infammatory agent KL-1037 represses proinfammatory cytokine and inducible nitric oxide synthase (iNOS) gene expression in activated microglia. Neuropharmacology. (2004) 47: 243-252.
29. Martindale JL and Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. J. Cell Physiol. (2002) 192: 1-15.
30. Choi Y, Lee MK, Lim SY, Sung SH and Kim YC. Inhibition of inducible NO synthase, cyclooxygenase-2 and interleukin-1beta by torilin is mediated by mitogen-activated protein kinases in microglial BV2 cells. Br. J. Phamrmacol. (2009) 156: 933-940.
31. Ajmone-Cat MA, De Simone R, Nicolini A and Minghetti L. Effects of phosphatidylserine on p38 mitogen activated protein kinase, cyclic AMP responding element binding protein and nuclear factor-kappaB activation in resting and activated microglial cells. J. Neurochem. (2003) 84: 413-416.
32. Aktan F. Inos-mediated nitric oxide production and its regulation. Life Sci. (2004) 75: 639-653.
33. Murakami A. Chemoprevention with phytochemicals targeting inducible nitric oxide synthase. Forum Nutr. (2009) 61: 193-203.
34. Phillis JW, Horrocks LA and Farooqui AA. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res. Rev. (2006) 52: 201-243.
35. Turini ME and DuBois RN. Cyclooxygenase-2: a therapeutic target. Annu. Rev. Med. (2002) 53: 35-57.
36. Rosenberg PB. Clinical aspects of infammation in Alzheimer>s disease. Int. Rev. Psychiatry. (2005) 17: 503-514.
37. Kim YS and Joh TH. Microglia, major player in the brain infammation: their roles in the pathogenesis of Parkinson>s disease. Exp. Mol. Med. (2006) 38: 333-347.
38. Sarkar FH, Li Y, Wang Z and Kong D. NF-kappaB signaling pathway and its therapeutic implications in human diseases. Int. Rev. Immunol. (2008) 27: 293-319.
39. Mankan AK, Lawless MW, Gray SG, Kelleher D and McManus R. NF-kappaB regulation: the nuclear response. J. Cell Mol. Med. (2009) 13: 631-643.
40. Baeuerle PA and Henkel T. Function and activation of NF-kappaB in the immune system. Annu. Rev. Immunol. (1994) 12: 141-179.
41. Baldwin Jr. AS. The NF-kappaB and I-kappaB proteins: new discoveries and insights. Annu. Rev. Immunol. (1996) 14: 649-683.
42. Moon DO, Park SY, Lee KJ, Heo MS, Kim KC, Kim MO, Lee JD, Choi YH and Kim GY. Bee venom and melittin reduce proinfammatory mediators in lipopolysaccharide-stimulated BV2 microglia. Int. Immunopharmacol. (2007) 7: 1092-1101.
43. Moon DO, Choi YH, Kim ND, Park YM and Kim GY. Anti-infammatory effects of beta-lapachone in lipopolysaccharide-stimulated BV2 microglia. Int. Immunopharmacol. (2007) 7: 506-514.
44. Jung WK, Ahn YW, Lee SH, Choi YH, Kim SK, Yea SS, Choi I, Park SG, Seo SK, Lee SW and Choi IW. Ecklonia cava ethanolic extracts inhibit lipopolysaccharide-induced cyclooxygenase-2 and inducible nitric oxide synthase expression in BV2 microglia via the MAP kinase and NF-kappaB pathways. Food Chem. Toxicol. (2009) 47: 410-417.
45. Zhou Y, Ling EA, Dheen ST. Dexamethasone suppresses monocyte chemoattractant protein-1 production via mitogen activated protein kinase phosphatase-1 dependent inhibition of Jun N-terminal kinase and p38 mitogen-activated protein kinase in activated rat microglia. J. Neurochem. (2007) 102: 667-678. This article is available online at http://www.ijpr.ir